Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
$6.49
-$0.34(-1.95%)
At close: 4:00 PM EST
$6.49
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.98 - $20.00
Previous CloseN/A
Volume45.37K
Average Volume (3M)135.98K
Market Cap
$168.76M
Enterprise Value$37.85M
Total Cash (Recent Filing)$143.38M
Total Debt (Recent Filing)$12.60M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Mar 05, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding26,003,607
10 Day Avg. Volume97,435
30 Day Avg. Volume135,979
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-68.21
Price to Sales (P/S)11.92
P/FCF Ratio-14.16
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue34.70
Enterprise Value/Gross Profit-3.23
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$35.00Price Target Upside439.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$672.57K
Bulls Say, Bears Say
Bulls Say
Clinical Trial Progress And Regulatory AlignmentEnrollment in a randomized Phase III program for Descartes-08 is underway and the program benefits from prior Phase II efficacy and an FDA-aligned Special Protocol Assessment, which could reduce regulatory execution risk if confirmatory results are achieved.
Expansion Into Additional Autoimmune And Pediatric IndicationsInitiation of a pediatric basket study and an FDA-accepted IND for myositis support a multi-indication development plan that could open paths into pediatric myositis and lupus beyond myasthenia gravis.
Safety Profile And Outpatient Treatment ModelMRNA-encoded Descartes-08 avoids genome integration and does not require lymphodepletion, enabling outpatient administration and a lower treatment-risk profile compared with traditional DNA CAR-T approaches, which may broaden patient access.
Bears Say
Competitive And Enrollment Challenges In SLE And Lupus NephritisHigh competition in systemic lupus erythematosus and difficulties finding fit-for-purpose patients for SLE and lupus nephritis trials increase execution risk for any future attempts to re-enter these indications.
Pipeline Narrowing And Reprioritization RiskDecision to pause the Descartes-15 program and to discontinue Descartes-08 development in SLE reflects a resource-focused strategy that reduces indication optionality and may limit long-term commercial diversification.
Safety Concerns Associated With T-cell Engager-like ToxicitiesCompany-identified risks around cytokine release syndrome, neurotoxicity, and severe infections linked to T-cell engager mechanisms could constrain clinical use and investor confidence in related cellular immunotherapies.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $5.98 and its highest was $20.00 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $168.76M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 23 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.847 by -$0.533.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 26,003,607 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.847. Following the earnings report the stock price went down -1.565%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (439.29% Upside)
$35.00 (439.29% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.15%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$35.00
▲(439.29% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
42.20% Insiders
10.98% Mutual Funds
6.09% Other Institutional Investors
37.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---